Singapore Market Focus

Singapore Market Focus

Refer to important disclosures at the end of this report

DBS Group Research . Equity

2 Mar 2021

STI: 2,973.87

Seasonal support ahead

- March and April are seasonally positive months
- S-REIT pullback presents opportunities
- Vaccine beneficiaries back in spotlight
- Stocks going ex-dividend

Dividend and seasonal trend support. Improving outlook for banks, upcoming ex-dividend period and a strong March-April seasonal trend point to a correction low in February at STI 2870, in line with our expectation. China's 13th National People's Congress (NPC) meeting this month will map out the development plan of technological independence and secure supply chains (e.g. semiconductors), sustainability and 'dual circulation'. The FED should leave rates unchanged at the FOMC meeting and maintain a dovish stance.

S-REIT pullback opportunities. We see opportunities amid the recent S-REIT pullback. S-REITs' yield spread of c.4.6% is the widest since 2013. The US 10-year yield spike should stabilise for now, as our interest rate strategist sees a 1.3-1.5% near-term range. Uncertainties are mostly priced in as our revised 2021 US 10-year yield target of 1.75% (previously 1.5%) is just 15bps above the 1.6% YTD high. Our picks are from sectors related to pandemic recovery such as retail (CLCT, LREIT) and hospitality (ART, CDL HT, FEHT, ARA US). Steeping of yield curve should augur well for banks' NIM (OCBC, UOB) in the longer term. Additionally, banks are expected to dish out higher dividends on the back of strong rebound in earnings in FY21.

Vaccine beneficiaries back in the spotlight. Rotational interest returns to aviation and hospitality stocks as the global COVID-19 vaccination drive continues to unfold. The number of COVID-19 infections has fallen amid warming weather in the northern hemisphere and the single-shot vaccine by Johnson & Johnson is the latest vaccine to be approved for public use by US CDC. We maintain our view that the US can be one of the first major developed countries to achieve herd immunity. Our picks are Prime US REIT and ARA US Hospitality Trust for US; ART, CDL HT and FHT for northern hemisphere; FEHT and CDL HT for Singapore, and MAGIC for Hong Kong. Outside of hospitality REITs, ComfortDelgro has 22.7% UK revenue exposure.

Going ex-dividend. Ceteris paribus, stocks with stronger upcoming dividend payouts should see an uptick in interest as their exdividend dates draw closer. For large caps, stocks with the highest upcoming dividend rates (%) and yields are Wilmar, ST Eng, Venture Corp, SembCorp Industries and UOL. For small caps, these are China Everbright, APAC Realty, CSE Global, Sasseur REIT, Frencken and Straits Trading.

Analyst

Kee Yan YEO, CMT +65 6682 3706 keeyan@dbs.com Woon Bing Yong +65 6682 3704 woonbingyong@dbs.com Janice CHUA +65 6682 3692 janicechuast@dbs.com

Key Indices

	Current	% Chng
FS STI Index	2974	0.0%
FS Small Cap Index	302	-0.7%
SGD Curncy	1.33	-0.1%
Daily Turnover (S\$m)	2,408	
Daily Turnover (US\$m)	1,674	
Source: Bloomberg Finance L.P.		

Market Key Data

(%)	EPS Gth	Div Yield
2020E	-46.5	3.4
2021F	80.1	4.1
2022F	19.1	4.4
(x)	PER	EV/EBITDA
(x) 2020E	PER 27.1	EV/EBITDA 20.4
` '	. =	

STOCKS

	Price	Mkt Cap	12-mth Target	Performance (%)		
	S\$	US\$m	S\$	3 mth	12 mth	Rating
Ascott Residence Trust	1.00	2,341	1.20	(4.3)	(15.7)	BUY
CDL Hospitality Trusts	1.23	1,134	1.35	(3.2)	(11.6)	BUY
Far East Hospitality Trust	0.59	865	0.70	(8.7)	(2.5)	BUY
ARA US Hospitality Trust	0.51	287	0.69	15.9	(32.0)	BUY
Prime US REIT	0.80	841	1.00	3.3	(17.3)	BUY
Venture Corporation	19.14	4,182	24.30	2.5	17.3	BUY
ComfortDelGro Mapletree North	1.60	2,611	1.99	(1.2)	(16.4)	BUY
Asia Commercial Trust	0.97	2,496	1.05	7.2	(12.3)	BUY
UOB	24.99	31,481	27.60	11.8	2.8	BUY
ST Engineering	19.14	4,182	24.30	2.5	17.3	BUY

Source: DBS Bank, Bloomberg Finance L.P. Closing price as of 2 Mar 2021








March Market Outlook

Recovery plays back in trend

- The STI rose 2.4% m-o-m to 2,973.54 (as of 25 February) as rising yields and an improved global pandemic outlook buoyed gains in the benchmark
- Industrials outperformed, led by improved container volumes at HPH Trust and a surge in vaccine recovery names (SIA, SATS)
- Banks (UOB, OCBC) gained as recovery optimism pushed 10year yields to a post-pandemic high
- •Consumer staples performed weaker in the month, potentially due to a rotation out of pandemic resilient names
- REITs underperformed as higher yields compressed yield spreads



All eyes on China and FOMC Meeting

- China's 13th National People's Congress
- Implementable policies to achieve goals of 14th Five Year Plan expected to be set out
- Key 14th Five -Year Plan themes include development of technological independence and secure supply chains (such as in semiconductors), sustainability and 'dual circulation'
- March FOMC Meeting
- Fed remains dovish even as COVID-19 vaccinations progress in the US
- Short-term rates not expected to rise until 2023

March event calendar

Date	Event	Comments
4 Mar	China's 13 th National People's Congress	Congress to set policies to achieve goals of 14 th Five- Year Plan
16 Mar	FOMC Meeting	Consensus not expecting negative rates

Source: Bloomberg Finance L.P., DBS Bank

Accommodative tone maintained at budget

 The government expects to incur a deficit of S\$11bn in FY21/22 to support Singapore's recovery

Key Measures:

- Jobs Support Scheme extension to primarily benefit aviation (SIA, SIA Engineering, SATS, ST Engineering) and tourism sectors (CDL HT, FEHT)
- Funding for on-arrival testing and biosafety systems to further boost aviation as air travel demand recovers
- GST on imported low-value goods will level the playing field for local retailers (Lendlease REIT, FCT)
- Enhanced public healthcare worker salaries raise cost pressure for private players (Raffles Medical, IHH)
- End of foreign worker levy waivers could raise labour costs at shipyards (Keppel, SMM)

Key Budget 2021 Measures


Measure	Details
Jobs	JSS subsidy extension to Sep 2021 of up
Support	to 30% depending on sector
Scheme	
Aviation	c.S\$870m in support for measures
Measures	including wage subsidies and on-arrival
	testing
GST on Low-	GST imposed on imported low-value
value Goods	goods from 1 Jan 2023
Increase in	Nurses and other healthcare workers
Healthcare	across public health institutions to
Wages	receive salary enhancements
Foreign	Waiver for foreign levies to taper off in
Worker Levy	2021

Source: Bloomberg Finance L.P., DBS Bank




Powell calms inflation nerves

- •FED Chair Powell says US economy is a 'long way' from central bank's goals → no plans to hike interest rates or taper bondbuying stimulus anytime soon
- ■Our interest rate strategist's current view
- US 10-year yield of 1.75% in 2021 (YTD high 1.6085%), near-term 1.3-1.5%
- 2Y/10Y yield spread could steepen further to 140-150bps
- FED could guide for taper in 2H21 and act in late 2021 to early 2022, rates to rise in 2023 → Watch for taper tantrum in 2H




- New global COVID-19 cases were generally on a decline as the US and UK peaked out in January 2021
- The improvement was also replicated in other countries including Germany, France, Japan and South Korea
- Going forward, we believe new global COVID-19 case counts will continue to drop on the back of rising temperatures in most of the top 15 economies

US 10-year yield – Interest rate strategist's forecast **OCCOMP NOR - LIFE TO SEE - L



UK and US current vaccination leaders


- ■140 doses per 100 people to achieve herd immunity assuming (1) two-dose vaccines, and (2) 70% population inoculation required
- ■UK (27 doses/100 people) and US (19.39 doses/100 people) currently leads the race to achieve population herd immunity
- Singapore is currently at 6.15 doses/100 people
- •Single-dose J&J vaccine could be the next vaccine approved for public use, speeding up the vaccination process, especially in the US





Seasonality trend points to February low

- •STI seasonality chart from 2011-2019 points to end-February low followed by recovery in March/April
- •March-April rise typically dividend-driven as stocks rise ahead of FY ex-dividend dates
- Refer to page 9 for companies with meaningful dividend payouts over the next two months



Straits Times Index Outlook

- •January pullback supported at 2870, coincides with our stated first support at 2880 and 13.78 (+0.5SD) 12-month forward PE
- •Seasonal trend suggests STI February low at 2870 and firming up in the March-April period heading towards the ex-dividend dates for index heavyweights
- Positive outlook from heavyweight banks should also underpin
 STI





Strategy

Pullback in S-REITs an opportunity

The FTSE ST REITs Index retreated as much as 7.8% from its 20 January high as inflation concerns led to a jump in US 10-year yield from 1.08% to as high as 1.60%. We see opportunities amid the pullback in S-REITs over the past 1.5 months because (1) Yield is rising from an absolute low level on the back of economic recovery optimism, (2) S-REITs' yield spread of c.4.6% is the widest since 2013, (3) The near-term spike in US 10-year yield should stabilise for now, as our interest rate strategist sees 1.3-1.5% near-term range, (4) Uncertainties mostly priced in – our revised 2021 US 10-year yield target of 1.75% (previously 1.5%) is just 15bps above the 1.6% YTD high, and (5) FED Chair Powell remains dovish, we expect short-term rates to rise only in 2023.

including retail (CLCT, LREIT,) and hospitality (ART, CDL HT, FEHT, ARA US) to ride on a recovery in DPUs. Office REITs such as MCT, with a diversified portfolio of Grade A and business park assets, are also preferred to capture demand from structural changes in the sector.

Among S-REITs, we prefer pandemic recovery sectors

Rising yields should also benefit banks (OCBC, UOB) as net interest margin (NIM) improves. Both OCBC and UOB have recently guided for a stabilisation in NIM for FY21 at around c.1.55%. Asset quality concerns are also improving with both banks erring on the safe side in recognising additional allowances in FY20. Additionally, the MAS cap on FY20 dividends (capped at 60% of FY19 DPS) may not be extended in FY21, which could be another catalyst to drive further upside for banking names.





Source: Bloomberg Finance L.P., DBS Bank

Yield Picks

Company	Price 25 Feb (S\$)	12-mth Target Price (S\$)	Target Return	Rcmd	PER 21 (x)	EPS Growth 21 (%)	Div Yield 21 (%)	Net Debt / Equity 21	P/BV 20 (x)
				R	ITs				
ART	1.00	1.20	20.0%	Buy	33.4	4.0	3.9	0.3	0.9
CDL HT	1.20	1.35	12.5%	Buy	39.3	nm	4.9	0.4	0.9
FCT	2.48	3.00	21.0%	Buy	17.3	8.9	5.2	0.4	1.1
LREIT	0.775	0.90	16.1%	Buy	21.0	281.2	6.7	0.3	0.9
MCT	2.04	2.25	10.3%	Buy	22.4	3.4	4.8	0.3	1.2
				Ba	ınks				
OCBC	11.07	11.90	7.5%	Buy	11.5	19.1	4.3	nm	1.0
UOB	24.65	26.80	8.7%	Buy	12.0	21.1	4.2	nm	1.0
Source: DBS I	Bank								



Vaccine beneficiaries back in the spotlight

Rotational interest is returning to aviation and hospitality stocks as the global COVID-19 vaccination drive continues to unfold and the single-shot vaccine by Johnson & Johnson becomes the latest vaccine to be approved by the US CDC, paving the way for public use. Aviation stocks **SATS** and **SIA** have led the current recovery.

We maintain our view that the US can be one of the first major developed countries to achieve herd immunity. Our picks are **Prime US REIT** and **ARA US Hospitality Trust** for US exposure.

Europe is making good progress with UK leading the global developed economies' vaccination drive. The coming of warm weather in the northern hemisphere and vaccine rollout among developed economies are positive for hospitality REITs with northern hemisphere exposure. **Ascott Residence Trust** has 28% US/Europe and 26% Japan/China

revenue exposure. **CDL HT** has 26% Europe and 4.1% Japan revenue exposure. **Frasers Hospitality Trust** has 20.4% Europe and 8.8% Japan revenue exposure. Outside of hospitality REITs, **ComfortDelgro** has 22.7% UK revenue exposure.

For Singapore, the resumption of more robust travel bubbles and reciprocal green lanes as soon as early 2Q are potential catalysts. Local staycation demand and the World Economic Forum in August are also positive drivers. Far East Hospitality Trust has 100% and CDL HT 42% Singapore revenue exposure.

The 7-day moving average of new COVID-19 infections in Hong Kong currently stands at 19 that is well above the <5 pre-condition for the SG-HK travel bubble to resume. With temperatures increasing in Hong Kong and the vaccination programme kicking off, we are cautiously optimistic that new infections will decline, and the travel bubbles will restart.

Mapletree NAC Trust benefits with a 55% revenue exposure.

Vaccine and declining COVID-19 infection beneficiaries

Company	Price 25 Feb	12-mth Target Price	Target Return	Mkt Cap (S\$m)	Rcmd	PER 21 (x)	PER 22 (x)	Growth	Div Yield 21 (%)	Net Debt / Equity 21	P/BV (x)
				US ex	posure	!					
Prime US REIT	0.800	1.00	25%	1,117	BUY	13.7	13.2	2.0	8.3	0.5	0.9
ARA US Hospitality	0.485	0.70	42%	363	BUY	nm	25.7	nm	5.6	0.5	0.6
			North	ern hemi	sphere	exposi	ıre				
ART	1.000	1.20	2%	318	BUY	33.4	17.9	4.7	3.9	0.3	0.9
CDL HT	1.200	1.35	13%	1,469	BUY	39.4	14.9	nm	4.9	0.4	1.0
FHT	0.510	0.70	37%	982	BUY	28.8	17.8	4.4	5.4	0.4	0.8
ComfortDelgro	1.620	1.99	23%	351	BUY	14.6	13.2	288.7	3.4	cash	1.3
				Singapor	e expos	sure					
FEHT	0.580	0.70	3%	1,139	BUY	27.0	2.2	6.8	4.8	0.4	0.7
CDL HT	1.200	1.35	13%	1,469	BUY	39.4	14.9	nm	4.9	0.4	1.0
			l	Hong Kor	ng expo	sure					
MAGIC Source: DBS Bank	0.970	1.50	8%	3,331	BUY	16.1	15.9	17.3	7.7	0.4	0.7



Going ex-dividend

STI seasonal trend (2011-2019) shows a positive return from March-April period as stocks rise ahead of their ex-dividend dates. This year should be no exception. Ceteris paribus, stocks with stronger upcoming dividend payouts should see an uptick in interest as their ex-dividend dates draw closer.

For large caps, stocks with the highest upcoming dividend rates (%) are Wilmar, ST Eng, Venture Corp, SembCorp Industries and UOL. For small caps, these are China Everbright, APAC Realty, CSE Global, Sasseur REIT, Frencken and Straits Trading.

Upcoming dividend payout by dollar amount

Upcoming dividend	d payout I	by dollar	amount				
Company	Price (\$) 26 Feb21	Dividend (\$)	Ex Date	Dividend rate (%)	Rec	12- mth Target Price	Upside (%)
CHINA EVERBRIGHT	0.225	0.01040	29-Apr-21	4.6%	BUY	0.340	51.3
APAC REALTY	0.445	0.01750	28-Apr-21	3.9%	BUY	0.613	37.7
CSE GLOBAL	0.500	0.01500	06-May-21	3.0%	BUY	0.636	27.3
WILMAR INTL	5.280	0.15500	23-Apr-21	2.9%	BUY	6.670	26.3
ST ENG	3.760	0.10000	27-Apr-21	2.7%	BUY	4.200	11.7
VENTURE CORP	19.200	0.50000	10-May-21	2.6%	BUY	24.300	26.6
SEMBCORP IND	1.730	0.04000	27-Apr-21	2.3%	BUY	1.855	7.2
SASSEUR REIT	0.840	0.01935	11-Mar-21	2.3%	BUY	0.900	7.1
FRENCKEN	1.350	0.03000	06-May-21	2.2%	BUY	1.554	15.1
STRAITS TRADING	2.780	0.06000	21-Apr-21	2.2%	BUY	3.896	40.1
UOL	7.390	0.15000	30-Apr-21	2.0%	BUY	8.400	13.7
EC WORLD REIT	0.725	0.01427	12-Mar-21	2.0%	BUY	0.800	10.3
SHENG SIONG	1.560	0.03000	07-May-21	1.9%	BUY	1.766	13.2
DELFI	0.745	0.01430	03-May-21	1.9%	BUY	0.959	28.8
TUAN SING	0.325	0.00600	07-May-21	1.8%	BUY	0.442	36.0
UOB	24.680	0.39000	06-May-21	1.6%	BUY	27.600	11.8
CITY DEV	7.360	0.12000	05-May-21	1.6%	BUY	10.500	42.7
OCBC	10.990	0.15900	12-May-21	1.4%	BUY	11.900	8.3
FIRST RESOURCES	1.450	0.02000	07-May-21	1.4%	BUY	1.830	26.2
KEPPEL CORP	5.080	0.07000	29-Apr-21	1.4%	HOLD	5.850	15.2
KOUFU	0.660	0.00700	04-May-21	1.1%	BUY	0.772	17.0
AEM	4.030	0.04000	14-May-21	1.0%	BUY	5.156	27.9
COMFORTDELGRO	1.610	0.01430	07-May-21	0.9%	BUY	1.990	23.6
UMS	1.150	0.01000	03-May-21	0.9%	BUY	1.362	18.4
IHH HEALTHCARE	5.080	0.04000	30-Mar-21	0.8%	BUY	6.150	21.1
IFAST	5.690	0.01000	03-May-21	0.2%	BUY	7.638	34.2
Source: DBS Bank							



DBS Bank recommendations are based on an Absolute Total Return* Rating system, defined as follows:

STRONG BUY (>20% total return over the next 3 months, with identifiable share price catalysts within this time frame)

BUY (>15% total return over the next 12 months for small caps, >10% for large caps)

HOLD (-10% to +15% total return over the next 12 months for small caps, -10% to +10% for large caps)

FULLY VALUED (negative total return, i.e., > -10% over the next 12 months)

SELL (negative total return of > -20% over the next 3 months, with identifiable share price catalysts within this time frame)

Completed Date: 2 Mar 2021 22:10:24 (SGT) Dissemination Date: 2 Mar 2021 22:37:22 (SGT)

Sources for all charts and tables are DBS Bank unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER

This report is prepared by DBS Bank Ltd. This report is solely intended for the clients of DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBS Bank Ltd.

The research set out in this report is based on information obtained from sources believed to be reliable, but we (which collectively refers to DBS Bank Ltd, its respective connected and associated corporations, affiliates and their respective directors, officers, employees and agents (collectively, the "DBS Group") have not conducted due diligence on any of the companies, verified any information or sources or taken into account any other factors which we may consider to be relevant or appropriate in preparing the research. Accordingly, we do not make any representation or warranty as to the accuracy, completeness or correctness of the research set out in this report. Opinions expressed are subject to change without notice. This research is prepared for general circulation. Any recommendation contained in this document does not have regard to the specific investment objectives, financial situation and the particular needs of any specific addressee. This document is for the information of addressees only and is not to be taken in substitution for the exercise of judgement by addressees, who should obtain separate independent legal or financial advice. The DBS Group accepts no liability whatsoever for any direct, indirect and/or consequential loss (including any claims for loss of profit) arising from any use of and/or reliance upon this document and/or further communication given in relation to this document. This document is not to be construed as an offer or a solicitation of an offer to buy or sell any securities. The DBS Group, along with its affiliates and/or persons associated with any of them may from time to time have interests in the securities mentioned in this document. The DBS Group, may have positions in, and may effect transactions in securities mentioned herein and may also perform or seek to perform broking, investment banking and other banking services for these companies.

Any valuations, opinions, estimates, forecasts, ratings or risk assessments herein constitutes a judgment as of the date of this report, and there can be no assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments. The information in this document is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed, it may not contain all material information concerning the company (or companies) referred to in this report and the DBS Group is under no obligation to update the information in this report.

This publication has not been reviewed or authorized by any regulatory authority in Singapore, Hong Kong or elsewhere. There is no planned schedule or frequency for updating research publication relating to any issuer.

The valuations, opinions, estimates, forecasts, ratings or risk assessments described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. It can be expected that one or more of the estimates on which the valuations, opinions, estimates, forecasts, ratings or risk assessments were based will not materialize or will vary significantly from actual results. Therefore, the inclusion of the valuations, opinions, estimates, forecasts, ratings or risk assessments described herein IS NOT TO BE RELIED UPON as a representation and/or warranty by the DBS Group (and/or any persons associated with the aforesaid entities), that:

- (a) such valuations, opinions, estimates, forecasts, ratings or risk assessments or their underlying assumptions will be achieved, and
- (b) there is any assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments stated therein.

^{*}Share price appreciation + dividends



Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Any assumptions made in this report that refers to commodities, are for the purposes of making forecasts for the company (or companies) mentioned herein. They are not to be construed as recommendations to trade in the physical commodity or in the futures contract relating to the commodity referred to in this report.

DBSVUSA, a US-registered broker-dealer, does not have its own investment banking or research department, has not participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months and does not engage in market-making.

ANALYST CERTIFICATION

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible for the content of this research report, in part or in whole, certifies that he or his associate¹ does not serve as an officer of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant) and the research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests² in relation to an issuer or a new listing applicant that the analyst reviews. DBS Group has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the DBS Group and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of DBS Group's compensation to any specific investment banking function of the DBS Group.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES

- 1. DBS Bank Ltd, DBS HK, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS") or their subsidiaries and/or other affiliates have proprietary positions in CapitaLand China Trust, LendLease Global Commercial REIT, Ascott Residence Trust, CDL Hospitality Trusts, ARA US Hospitality Trust, OCBC, UOB, Prime US REIT, Frasers Hospitality Trust, Mapletree North Asia Commercial Trust, ComfortDelgro, Wilmar International, ST Engineering, Venture Corporation, Sembcorp Industries, UOL Group, Sasseur REIT, Hutchison Port Holdings Trust, Singapore Airlines Limited, SATS, Frasers Centrepoint Trust, Keppel Corporation, Sembcorp Marine, Mapletree Commercial Trust, Sheng Siong Group, City Developments recommended in this report as of 31 Jan 2021.
- 2. Neither DBS Bank Ltd nor DBS HK market makes in equity securities of the issuer(s) or company(ies) mentioned in this Research Report.
- 3. DBS Bank Ltd, DBS HK, DBSVS, their subsidiaries and/or other affiliates have a net long position exceeding 0.5% of the total issued share capital in CapitaLand China Trust, ARA US Hospitality Trust, Prime US REIT, Frasers Hospitality Trust, Mapletree North Asia Commercial Trust, ComfortDelgro, Sasseur REIT, Frasers Centrepoint Trust, Mapletree Commercial Trust recommended in this report as of 31 Jan 2021.
- 4. DBS Bank Ltd, DBS HK, DBSVS, DBSVUSA or their subsidiaries and/or other affiliates beneficially own a total of 1% of any class of common equity securities of ARA US Hospitality Trust, Prime US REIT, Frasers Hospitality Trust, Sasseur REIT, Frasers Centrepoint Trust as of 31 Jan 2021.

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial interest is defined as interests that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.



Compensation for investment banking services:

- 5. DBS Bank Ltd, DBS HK, DBSVS their subsidiaries and/or other affiliates of DBSVUSA have received compensation, within the past 12 months for investment banking services from CapitaLand China Trust, Prime US REIT, Wilmar International, ST Engineering, Sembcorp Industries, The Straits Trading Company Limited, Singapore Airlines Limited, SATS, Frasers Centrepoint Trust, Keppel Corporation, Sembcorp Marine, City Developments, Koufu Group Limited as of 31 Jan 2021.
- 6. DBS Bank Ltd, DBS HK, DBSVS, their subsidiaries and/or other affiliates of DBSVUSA have managed or co-managed a public offering of securities for Prime US REIT, Wilmar International, ST Engineering, The Straits Trading Company Limited, Singapore Airlines Limited, SATS, Frasers Centrepoint Trust, Keppel Corporation, Sembcorp Marine, City Developments in the past 12 months, as of 31 Jan 2021.
- 7. DBSVUSA does not have its own investment banking or research department, nor has it participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months. Any US persons wishing to obtain further information, including any clarification on disclosures in this disclaimer, or to effect a transaction in any security discussed in this document should contact DBSVUSA exclusively.

Directorship/trustee interests:

- 8. Su Shan TAN, a member of DBS Group Management Committee, is a Director of Mapletree North Asia Commercial Trust as of 01 Feb 2021
- 9. Sim S. LIM, a member of DBS Group Management Committee, is a Independent non-executive director of ST Engineering as of 01 Feb 2021.
- 10. Peter Seah Lim Huat, Chairman & Director of DBS Group Holdings, is a Director / Chairman of Singapore Airlines Limited as of 31 Dec 2020
- 11. Euleen Goh Yiu Kiang, a member of DBS Group Holdings Board of Directors, is a Non-Exec Director / Chairman of SATS as of 31 Dec 2020.
- 12. Olivier Lim Tse Ghow, a member of DBS Group Holdings Board of Directors, is a Non-Exec Director of Raffles Medical as of 31 Dec 2020
- 13. Tham Sai Choy, a member of DBS Group Holdings Board of Directors, is a Director of Keppel Corporation as of 31 Dec 2020.

Disclosure of previous investment recommendation produced:

14. DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS"), their subsidiaries and/or other affiliates may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS"), their subsidiaries and/or other affiliates in the preceding 12 months.



RESTRICTIONS ON DISTRIBUTION

General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is being distributed in Australia by DBS Bank Ltd, DBSVS or DBSV HK. DBS Bank Ltd holds Australian Financial Services Licence no. 475946. DBSVS and DBSV HK are exempted from the requirement to hold an Australian Financial Services Licence under the Corporation Act 2001 ("CA") in respect of financial services provided to the recipients. Both DBS Bank Ltd and DBSVS are regulated by the Monetary Authority of Singapore under the laws of Singapore, and DBSV HK is regulated by the Hong Kong Securities and Futures Commission under the laws of Hong Kong, which differ from Australian laws. Distribution of this report is intended only for "wholesale investors" within the meaning of the CA.
Hong Kong	This report has been prepared by a person(s) who is not licensed by the Hong Kong Securities and Futures Commission to carry on the regulated activity of advising on securities in Hong Kong pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). This report is being distributed in Hong Kong and is attributable to DBS Bank (Hong Kong) Limited, a registered institution registered with the Hong Kong Securities and Futures Commission to carry on the regulated activity of advising on securities pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). DBS Bank Ltd., Hong Kong Branch is a limited liability company incorporated in Singapore. For any query regarding the materials herein, please contact Carol Wu (Reg No. AH8283) at dbsvhk@dbs.com
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is distributed in Malaysia by AllianceDBS Research Sdn Bhd ("ADBSR"). Recipients of this report, received from ADBSR are to contact the undersigned at 603-2604 3333 in respect of any matters arising from or in connection with this report. In addition to the General Disclosure/Disclaimer found at the preceding page, recipients of this report are advised that ADBSR (the preparer of this report), its holding company Alliance Investment Bank Berhad, their respective connected and associated corporations, affiliates, their directors, officers, employees, agents and parties related or associated with any of them may have positions in, and may effect transactions in the securities mentioned herein and may also perform or seek to perform broking, investment banking/corporate advisory and other services for the subject companies. They may also have received compensation and/or seek to obtain compensation for broking, investment banking/corporate advisory and other services from the subject companies.
	Wong Ming Tek, Executive Director, ADBSR



Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 196800306E) or DBSVS (Company Regn No. 198600294G), both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, DBS Bank Ltd accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is produced by DBS Bank Ltd which is regulated by the Monetary Authority of Singapore. This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608 - 610, 6 th Floor, Gate Precinct Building 5, PO Box 506538, DIFC, Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	This report was prepared by DBS Bank Ltd. DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.



DBS Regional Research Offices

HONG KONG DBS (Hong Kong) Ltd

Contact: Carol Wu 13th Floor One Island East, 18 Westlands Road, Quarry Bay, Hong Kong Tel: 852 3668 4181 Fax: 852 2521 1812

e-mail: dbsvhk@dbs.com

THAILAND DBS Vickers Securities (Thailand) Co Ltd

Contact: Chanpen Sirithanarattanakul 989 Siam Piwat Tower Building, 9th, 14th-15th Floor Rama 1 Road, Pathumwan, Bangkok Thailand 10330 Tel. 66 2 857 7831

Fax: 66 2 658 1269 e-mail: research@th.dbs.com Company Regn. No 0105539127012 Securities and Exchange Commission,

Thailand

MALAYSIA

AllianceDBS Research Sdn Bhd

Contact: Wong Ming Tek 19th Floor, Menara Multi-Purpose, Capital Square, 8 Jalan Munshi Abdullah 50100 Kuala Lumpur, Malaysia.

Tel.: 603 2604 3333 Fax: 603 2604 3921

e-mail: general@alliancedbs.com Co. Regn No. 198401015984

(128540-U)

INDONESIA

PT DBS Vickers Sekuritas (Indonesia)

Contact: Maynard Priajaya Arif DBS Bank Tower Ciputra World 1, 32/F Jl. Prof. Dr. Satrio Kav. 3-5 Jakarta 12940, Indonesia Tel: 62 21 3003 4900 Fax: 6221 3003 4943

e-mail: indonesiaresearch@dbs.com

SINGAPORE DBS Bank Ltd

Contact: Janice Chua 12 Marina Boulevard, Marina Bay Financial Centre Tower 3 Singapore 018982 Tel: 65 6878 8888 e-mail: groupresearch@dbs.com Company Regn. No. 196800306E